



Supplementary Material

Article Title: Adjunctive Taurine in First-Episode Psychosis:
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study

Author(s): Colin P. O'Donnell, MBBCh, MSc, MRCPsych; Kelly A. Allott, DPsych;
Brendan P. Murphy, MD; Hok Pan Yuen, MSc; Tina-Marie Proffitt, DPsych;
Alicia Papas, DPsych; Jennifer Moral, DPsych; Tee Pham, DPsych;
Michaela K. O'Regan, DPsych; Christina Phassouliotis, DPsych;
Raelene Simpson, PhD; and Patrick D. McGorry, MD, PhD

DOI Number: [dx.doi.org/10.4088/JCP.15m10185](https://doi.org/10.4088/JCP.15m10185)

List of Supplementary Material for the article

1. [eTable 1](#) Side Effects at Weeks 6 and 12 Based on the UKU Scale and Logistic Regression Analyses

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary Table. Side effects at weeks 6 and 12 based on the UKU scale and logistic regression analyses

UKU Domain	UKU Item	Group	% of participants having the symptom (i.e., severity score ≥1)			Logistic regression p-value*	
			Baseline	Week 6	Week 12	Week 6	Week 12
Psychic	1	Taurine	14.0	4.7	2.3	.827	NA
		Placebo	9.3	4.7	1.2		
	2	Taurine	22.1	9.3	4.7	.922	.006
		Placebo	16.3	8.1	14.0		
	3	Taurine	10.5	3.5	2.3	NA	.088
		Placebo	8.1	2.3	8.1		
	4	Taurine	8.1	3.5	1.2	.729	NA
		Placebo	10.5	3.5	1.2		
	5	Taurine	5.8	3.5	0	.794	NA
		Placebo	5.8	3.5	1.2		
	6	Taurine	9.3	3.5	3.5	NA	NA
		Placebo	5.8	2.3	2.3		
	7	Taurine	5.8	4.7	2.3	.478	.790
		Placebo	8.1	2.3	4.7		
	8	Taurine	2.3	1.2	0	NA	NA
		Placebo	2.3	2.3	0		
	9	Taurine	4.7	1.2	1.2	NA	NA
		Placebo	5.8	2.3	2.3		
	10	Taurine	3.5	1.2	1.2	NA	NA
		Placebo	4.7	3.5	1.2		
Neurological	1	Taurine	1.2	0	1.2	NA	NA
		Placebo	1.2	1.2	1.2		
	2	Taurine	3.5	1.2	1.2	NA	NA

Autonomic		Placebo	1.2	1.2	0		
	3	Taurine	3.5	1.2	0	NA	NA
		Placebo	2.3	0	0		
	4	Taurine	1.2	1.2	0	NA	NA
		Placebo	3.5	1.2	0		
	5	Taurine	3.5	2.3	1.2	NA	NA
		Placebo	3.5	2.3	1.2		
	6	Taurine	1.2	0	1.2	NA	NA
		Placebo	1.2	0	1.2		
	7	Taurine	0	0	0	NA	NA
		Placebo	0	0	0		
	8	Taurine	0	0	0	NA	NA
		Placebo	0	0	0		
	1	Taurine	2.3	0	0	NA	NA
		Placebo	0	0	0		
	2	Taurine	4.7	2.3	1.2	NA	NA
		Placebo	1.2	2.3	2.3		
	3	Taurine	9.3	2.3	1.2	NA	NA
		Placebo	2.3	3.5	1.2		
	4	Taurine	3.5	3.5	0	NA	NA
		Placebo	4.7	2.3	2.3		
	5	Taurine	0	1.2	0	NA	NA
		Placebo	2.3	0	1.2		
	6	Taurine	1.2	3.5	1.2	NA	NA
		Placebo	1.2	0	0		
	7	Taurine	0	0	1.2	NA	NA
		Placebo	0	0	0		

Other	8	Taurine	2.3	1.2	0	NA	NA
		Placebo	2.3	1.2	0		
	9	Taurine	7.0	3.5	1.2	NA	NA
		Placebo	5.8	2.3	4.7		
	10	Taurine	2.3	0	0	NA	NA
		Placebo	2.3	2.3	1.2		
	11	Taurine	4.7	2.3	1.2	NA	NA
		Placebo	1.2	0	0		
	1a	Taurine	0	0	0	NA	NA
		Placebo	0	0	0		
	1b	Taurine	0	0	0	NA	NA
		Placebo	0	0	0		
	1c	Taurine	0	0	0	NA	NA
		Placebo	0	0	0		
	1d	Taurine	0	0	0	NA	NA
		Placebo	0	0	0		
	1e	Taurine	0	0	0	NA	NA
		Placebo	1.2	0	0		
	2	Taurine	1.2	0	0	NA	NA
		Placebo	0	0	0		
	3	Taurine	2.3	2.3	1.2	NA	NA
		Placebo	1.2	0	1.2		
	4	Taurine	0	0	0	NA	NA
		Placebo	0	0	0		
	5	Taurine	10.5	5.8	7	.353	.520
		Placebo	4.7	2.3	5.8		
	6	Taurine	2.3	1.2	1.2	NA	NA

	Placebo	0	0	1.2		
7	Taurine	1.2	0	0	NA	NA
	Placebo	0	0	0		
8	Taurine	3.5	2.3	0	NA	NA
	Placebo	2.3	0	0		
9	Taurine	0	0	0	NA	NA
	Placebo	0	0	0		
10	Taurine	0	0	0	NA	NA
	Placebo	1.2	1.2	0		
11	Taurine	1.2	1.2	0	NA	NA
	Placebo	0	0	0		
12	Taurine	5.8	2.3	0	NA	NA
	Placebo	3.5	3.5	4.7		
13	Taurine	0	0	0	NA	NA
	Placebo	0	2.3	2.3		
14	Taurine	0	0	0	NA	NA
	Placebo	0	0	1.2		
15	Taurine	0	0	0	NA	NA
	Placebo	0	0	1.2		
16	Taurine	1.2	1.2	0	NA	NA
	Placebo	0	0	0		
17a	Taurine	3.5	1.2	0	NA	NA
	Placebo	4.7	1.2	0		
17b	Taurine	0	0	1.2	NA	NA
	Placebo	0	0	0		
17c	Taurine	0	0	0	NA	NA
	Placebo	0	0	0		

	18	Taurine	0	0	0	NA	NA
		Placebo	0	0	0		
	19	Taurine	0	0	0	NA	NA
		Placebo	0	0	0		

*The p-values are for testing for group difference using logistic regression with baseline score as a covariate.

'NA' means that logistic regression was not done because the number of participants having the symptom at the time point concerned is less than 6.